Fig. 10
UPS is upregulated and MG-132 treatment improves the swimming behavior and dystrophic phenotype of caf mutants. (A and B) Western blot analysis showing increased levels of Polyubiquitinylated proteins (PolyU) in caf mutants. (C–E) Swimming behavior analysis. (C) There is no significant improvement in time spent swimming in caf mutants treated with 10 μM MG132 (n = 166). (D and E) There are significant improvements in distance traveled and average velocity in caf mutants at 3 dpf after treatment with 10 μM MG132. (F) Treatment with 10 μM MG132 improves the dystrophic phenotype of caf mutants at 3 dpf but does not restore muscle integrity to WT levels (n = 43). **P < 0.0075; ****P < 0.0001. Bars represent mean ± SEM.